- Home
- HMR vs RCEL Comparison
HMR vs RCEL Comparison
Compare HMR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMR
- RCEL
- Stock Information
- Founded
- HMR 1984
- RCEL N/A
- Country
- HMR Greece
- RCEL United States
- Employees
- HMR N/A
- RCEL N/A
- Industry
- HMR Marine Transportation
- RCEL Medical/Dental Instruments
- Sector
- HMR Consumer Discretionary
- RCEL Health Care
- Exchange
- HMR Nasdaq
- RCEL Nasdaq
- Market Cap
- HMR 159.3M
- RCEL 170.8M
- IPO Year
- HMR N/A
- RCEL N/A
- Fundamental
- Price
- HMR $1.89
- RCEL $5.62
- Analyst Decision
- HMR Strong Buy
- RCEL Strong Buy
- Analyst Count
- HMR 1
- RCEL 4
- Target Price
- HMR $7.00
- RCEL $17.25
- AVG Volume (30 Days)
- HMR 133.7K
- RCEL 347.9K
- Earning Date
- HMR 01-01-0001
- RCEL 05-08-2025
- Dividend Yield
- HMR N/A
- RCEL N/A
- EPS Growth
- HMR N/A
- RCEL N/A
- EPS
- HMR 96.00
- RCEL N/A
- Revenue
- HMR $28,949,873.00
- RCEL $71,661,000.00
- Revenue This Year
- HMR N/A
- RCEL $59.50
- Revenue Next Year
- HMR N/A
- RCEL $28.89
- P/E Ratio
- HMR $0.02
- RCEL N/A
- Revenue Growth
- HMR N/A
- RCEL 41.35
- 52 Week Low
- HMR $1.45
- RCEL $5.46
- 52 Week High
- HMR $10.04
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- HMR N/A
- RCEL 25.54
- Support Level
- HMR N/A
- RCEL $6.06
- Resistance Level
- HMR N/A
- RCEL $6.38
- Average True Range (ATR)
- HMR 0.00
- RCEL 0.47
- MACD
- HMR 0.00
- RCEL -0.11
- Stochastic Oscillator
- HMR 0.00
- RCEL 8.12
About HMR Heidmar Maritime Holdings Corp. Common Stock
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. It is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.